[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-neuropathic-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100556915","machine-learning-based-eeg-biomarkers-for-personalized-interventions-100556915",false,"NCT06531317","Machine-Learning Based EEG Biomarkers for Personalized Interventions","EEG-INSIGHT","Inclusion Criteria:\n\n* Age: Over 18 years old.\n* Neuropathic Pain (NP): Subacute NP at or below the lesion level for at least 1 month following spinal cord injury or disease. Persistent NP is defined as pain in an area of sensory abnormality corresponding to the spinal cord injury according to international criteria (Bryce et al. 2012). The pain should not be primarily related to spasms or any other movement.\n* Pain Intensity: At least 4 out of 10 on the Numerical Rating Scale (NRS) at the time of screening (rated during the previous 24 hours).\n* Pharmacological Treatment: Stable treatment including antiepileptic, antidepressant, or antispastic drugs (Gabapentin (GBP) with a minimum dose of 900 mg\u002Fday, Pregabalin (PGB) with a minimum dose of 150 mg\u002Fday, Amitriptyline with a minimum dose of 25 mg\u002Fday). No dose changes for at least 2 weeks prior to treatment and no additional antiepileptic medication. The pharmacological regimen must be maintained without changes during the 10-day stimulation period and until the electrophysiological measurement. It is recommended to keep the regimen stable until the completion of the following two evaluations (4 and 12 weeks after the end of treatment). Only paracetamol or anti-inflammatory drugs are allowed as rescue treatment.\n\nExclusion Criteria:\n\n* Patients with severe pain (NRS \\> 7) from other sources, such as musculoskeletal pain, inflammatory pain, or cancer-related pain.\n* Subjects with traumatic brain injury.\n* Subjects with alcohol abuse.\n* Subjects with neurological diseases other than the specified spinal cord injury.\n* Subjects with substance abuse.\n* Subjects with any other chronic medical condition where transcranial tDCS is relatively contraindicated, such as pregnancy or epilepsy.","ALL","18 Years","99 Years",{"count":20,"type":21},58,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to develop a machine learning model to predict the outcome of a transcranial direct current stimulation (tDCS) treatment in patients suffering from neuropathic pain derived from a spinal cord injury. The main question it aims to answer is:\n\n• Can electroencephalography (EEG) and clinical assessment data predict the success of tDCS treatment in neuropathic pain patients?\n\nParticipants will:\n\n* Undergo EEG recording sessions to collect brain activity data before treatment.\n* Complete clinical assessments, including medical diagnostics and questionnaires focused on factors related to neuropathic pain before and after treatment.",[25,26,27],"Neuropathic Pain","Spinal Cord Injuries","Central Neuropathic Pain",[25,29,30,31,32],"EEG","Machine Learning","Spinal Cord Injury","tDCS","RECRUITING","2024-07-30",{"date":36,"type":37},"2024-07-31","ACTUAL",{"date":39,"type":37},"2023-10-05",{"date":41,"type":21},"2025-11-07",{"name":43,"class":44},"Institut Guttmann","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100548524","phase-3-efficacy-and-safety-of-hsk16149-capsule-in-the-treatment-of-moderate-and-severe-central-neuropathic-pain-in-china-100548524","NCT06422117","Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China","Inclusion Criteria:\n\n1. Voluntarily sign an informed consent form;\n2. Able to read and complete survey questionnaires;\n3. Male or female patients aged ≥ 18 years old;\n4. The subject has a medical history and symptoms related to central neuropathic pain, including spinal cord related neuropathic pain (subject enrollment ≥ 50%), post-stroke central neuropathic pain, Parkinson's disease pain, and multiple sclerosis pain, and must meet the following criteria: a) pain duration ≥ 3 months; b) Characteristics that conform to neuropathic pain: DN4 scale score ≥ 4 points;\n5. During screening visits, patients were assessed to have an average pain visual analogue scale (VAS) score of ≥ 40 mm over the past 24 hours.\n\nExclusion Criteria:\n\n1. The presence of other painful diseases that may affect the evaluation of neuropathic pain;\n2. Patients with spinal cord injury or stroke whose condition is unstable and is expected to require surgical treatment;\n3. There is a chronic systemic disease that the investigator has assessed may affect the participant's participation in the study；\n4. Meet any of the following laboratory test results: a) Hematology: WBC\\\u003C3×109\u002FL, N\\\u003C 1.5 ×109\u002FL, PLT\\\u003C 75 ×109\u002FL, or HB\\\u003C 90 g\u002FL; b) Liver function: ALT or AST\\> 2.5 × ULN; Or TBIL\\> 1.5 × ULN; c) eGFR\\\u003C 60 mL\u002Fmin\u002F1.73 m2; d) Creatine kinase \\> 2.0 × ULN;\n5. Women who are pregnant, planning to become pregnant during the study period, or breastfeeding; Women who do not wish to use reliable contraceptive methods (including condoms, spermicides, or Iuds) for 28 days after signing up for the ICF from the beginning to the last trial drug administration, or who plan to use progesterone contraceptives during this period;\n6. Mechanical operators engaged in high-altitude work, motor vehicle driving and other dangerous activities during the study period;\n7. Participated in any other clinical study within 30 days prior to screening;\n8. The investigator determined that there were other conditions that were not suitable for study participation.",{"count":54,"type":21},408,"INTERVENTIONAL",[57],"PHASE3","To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.",[27],"NOT_YET_RECRUITING","2024-05-17",{"date":63,"type":37},"2024-05-20",{"date":65,"type":21},"2024-05-30",{"date":67,"type":21},"2027-08-07",{"name":69,"class":70},"Haisco Pharmaceutical Group Co., Ltd.","INDUSTRY"]